Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.55 |
| ▸ | CCR8 | P51685 | 5/20 | 0.55 |
| ▸ | CCR5 | P51681 | 3/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874272 | 0.80 | PSMD14 (0.67) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL12093369 | 0.78 | CCR1 (0.56) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL12847065 | 0.78 | CCR1 (0.51) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL3347624 | 0.77 | KDM4E (0.57) | CCR1CCR8CCR5LMNAHTT | |
| SCHEMBL2938512 | 0.77 | LMNA (0.56) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL19001540 | 0.77 | CCR1 (0.55) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL5544307 | 0.77 | CCR1 (0.55) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL5544300 | 0.77 | CCR1 (0.55) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL17092795 | 0.77 | CCR1 (0.55) | CCR1CCR8CCR5PSMD14COPS5 | |
| SCHEMBL1148955 | 0.77 | CCR1 (0.45) | CCR1CCR8CCR5PSMD14COPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253681-A | Synthesis method of 6-amino-8-difluoromethyl quinoline | 苏州康润医药有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-12448392-B2 | Spiropiperidine derivatives | CEPHALON LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4562017-A1 | NOVEL ACC INHIBITORS | Pfizer Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120019059-A | Novel ACC inhibitors | 辉瑞公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (GB) | 2024-11-28 | — | — | US | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-20240166661-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023727-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009633-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009633-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-5523312-A | ADMINISTERING TO MAMMALS | STERLING WINTHROP INC. (US) | 1996-06-04 | — | — | US | disclosed |
| US-5514692-A | VIRICIDES | STERLING WINTHROP INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1996009822-A1 | ANTIPICORNAVIRAL AGENTS | SANOFI WINTHROP, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | CCR1 736/4885CCR8 1009/4885CCR5 1343/4885 |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | CCR1 590/4885CCR8 994/4885CCR5 1565/4885 |
| US-12448392-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | CCR1 3705/4885CCR8 4323/4885CCR5 2775/4885 |
| US-20240166661-A1 | Spiropiperidine Derivatives | FASN, FADS2, SCD5 | CCR1 3705/4885CCR8 4323/4885CCR5 2775/4885 |
| US-20240391940-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | CCR1 2573/4885CCR8 1437/4885CCR5 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.